Practitioner's Docket No. 2003IT301

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re	application o	^{of:} Giorgio BERTOLIN		
			Examiner:	
	cation No.:		Group No.:	
Filed:	•	09/24/2005		
For:	PROCESS	AND INTERMEDIATES FO	R PREPARING EMTRICITABINE	

Commissioner for Patent P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

	•	MAILING		
e	deposited with the United States Postal Son 1450, Alexandria, VA 22313-1450.	ervice in an envelope add	ressed to the Commissioner for Patents, P.O.	
	37 C.F.R. section 1.8(a)		37 C.F.R. section 1.10*	
	with sufficient postage as first class mail.	Ø	as "Express Mail Post Office to Address" Mailing Label No (mandatory)	
		TRANSMISSION	ED795251473	US
	transmitted by facsimile to the Patent and	Trademark Office (703)	<u>872-930</u> 6	
Date: _	9-23-05	Sin	1500	
		Signati (type o.	vicki Saro r print name of person ceraliying)	
*WAR	NING: Each paper or fee filed by "Exp placed thereon prior to mailing	ress Mail" must have the	number of the "Express Mail" mailing label	

"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

10/550718 JC12 Rec'd PCT/PTC 2.3 SEP 2005
Applicant: Giorgio BERTOLINI

Serial No.

Filed 09/24/2005

Page 2

Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1.	V	Enclosures accompanying this Information Disclosure Statement are: 1a.
2.	7	This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3.		This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
1 .		This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5.		This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6.		This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.
7.		The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached 1449 Form are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached 1449 Form.
3.		In addition to the documents cited, the Office's attention is directed to the following co-pending U.S. Application Serial Number(s), copies of which are attached for the convenience of the Office:

Respectfully submitted

Richard P. Silverman, Registration No. 36,277

10/550718 JC12 Rec'd PCT/PTC 23 SEP 2005

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

s	ubstitute for form 1449A/PTO)	Complete if Known		
			Application Number		
1	NEORMATION	N DISCLOSURE	Filing Date	09/24/2005	
-	· · · · · · · · · · · · · · · · · ·	BY APPLICANT	First Named Inventor	Giorgio BERTOLINI	
•) : A I E IVI E IVI I	JI ALLEOART	Art Unit		
	(Use as many sh	eets as necessary)	Examiner Name		
Sheet	1 ',	of 2	Attorney Docket Number	2003 T301 ·	一丿

U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
/VB/	AA	^{US-} 5,204,466	04/20/1993	LIOTTA				
	AB	^{US-} 5,696,254	12/09/1997	MANSOUR				
	AC	^{US-} 6,051,709	04/18/2000	GOODYEAR				
	AD	^{US-} 5,538,975	07/23/1996	Dionne				
A.M.	ΑE	^{US-} 6,329,522	12/11/2001	Hill				
	AF	US- 5,852,027	12/22/1998	Liotta				
/VB/	AG	US- 5,892,025	04/06/1999	Liotta				
	АН	US-						
	Al	US-						
	AJ	US-						
	AK	US-						
	AL	US-						
	AM	US-						
	AN	US-						
	AO	US-						
	AP	US-						
	AQ	US-						
	AR	US-						

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ 'Number ⁴ 'Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	™			
/VB/	ВА	EP 0515157	11/25/1992	Biochem Pharma					
	вв				***************************************				
**************************************	вс				***************************************				
·····	BD		D-2010404040404040404040	P*************************************	**************************************				
*****************	BE								

Examiner Signature	/Venkataraman Balasubramanian/	Date Considered	03/14/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

JC12 Rec'd PCT/PTC 2 3 SFP 2005

Approved for use through 07/31/2006. OMB 6651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Subsut	16 101 101111 1449/F 10			Application Number		
INF	ORMATION	DIS	CLOSURE	Filing Date	09/24/2005	
STA	STATEMENT BY APPLICANT			First Named Inventor	Giorgio BERTOLINI	
				Art Unit		
(Use as many sheets as necessary)			ecessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	2003IT301	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
/VB/	CA	CHU, CK; et al., "Synthesis and Antiviral Activity of Oxaselenolane Nucleosides", J. Med. Chem., 2000, pp 3906-3912, Vol. 43	13	
/VB/	СВ	Jeong, LS; et al., "Asymmetric Synthesis and Biological Evaluation of Beta-L-(2R,5S)- and Alpha-L-(2,R,5R-1,3-Oxathiolane-Pyrimidine", J. Med Chem.,1993, pp181-195, V36, N2		
	СС			
	CD			
	CE			
	CF	·		
	CG	•		
	СН			
	СІ			
	CJ			

Examiner		Date	
Signature	/Venkataraman Balasubramanian/	Considered	03/14/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.